Prospective Analysis of a Combination Therapy Protocol of Lopinavir/Ritonavir, Chloroquine Phosphate, and Ribavirin on COVID-19 Patients
| Author | Mandana Pouladzadeh | en |
| Author | Mehdi Safdarian | en |
| Author | Ziya Azizi | en |
| Author | Kambiz Masoumi | en |
| Author | Parastoo Moradi Choghakabodi | en |
| Author | Alireza Sokooti | en |
| Author | Farid Yousefi | en |
| Orcid | Mehdi Safdarian [0000-0001-9735-2632] | en |
| Issued Date | 2024-06-30 | en |
| Abstract | Background: Timely diagnosis and treatment of coronavirus disease 2019 (COVID-19) present significant global medical challenges. Objectives: This study aimed to evaluate the laboratory markers and clinical outcomes in COVID-19 patients treated with a combination therapy protocol comprising lopinavir/ritonavir, chloroquine (CQ) phosphate, and ribavirin. Methods: In this single-arm prospective study, out of 127 COVID-19 patients recruited, 122 were comprehensively assessed for clinical and laboratory changes from the day of admission (prior to medication initiation) to the ninth day of treatment. Results: Overall, the levels of lymphocytes, lactate dehydrogenase (LDH), interleukin (IL)-6, IL-10, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were significantly modulated after treatment compared to baseline levels (P < 0.05). Disease severity was not significantly correlated with sex (P = 0.85) or age (P = 0.47), but it was strongly associated with underlying health conditions [P = 0.005, OR (95% CI): 2.96 (1.39 - 6.31)]. Among all biomarkers, only CRP showed a significant correlation with age (P = 0.03), with greater modulation observed in patients over 50 years. The survival rate was 94.3%, with 7 patient fatalities (5.7%). Conclusions: The combination therapy protocol of lopinavir/ritonavir, chloroquine phosphate, and ribavirin may modulate cytokine levels and hematological markers in COVID-19 patients. However, further investigation is required to draw conclusions about its impact on clinical outcomes. | en |
| DOI | https://doi.org/10.69107/jjp-157756 | en |
| Keyword | COVID-19 | en |
| Keyword | Chloroquine Phosphate | en |
| Keyword | Lopinavir-Ritonavir | en |
| Keyword | Ribavirin | en |
| Keyword | Biomarkers | en |
| Keyword | Cytokines | en |
| Publisher | Brieflands | en |
| Title | Prospective Analysis of a Combination Therapy Protocol of Lopinavir/Ritonavir, Chloroquine Phosphate, and Ribavirin on COVID-19 Patients | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- jjp-3-1-157756-publish-pdf.pdf
- Size:
- 333.5 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF